On Tuesday, December 4th, oral arguments were held before the U.S. Supreme Court in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA. The nation’s highest court will determine whether a secret sale of an invention, or a sale of a technology under terms that require the invention to remain confidential, triggers the on-sale bar under 35 U.S.C. § 102(a)(1), thereby preventing the invention from being patented. With this question squarely before the Supreme Court, several members of the legal industry who are watching this case offer their views on the major takeaways and the potential consequences of the Supreme Court’s decision, which will issue next year.
The post Industry Reaction to Helsinn Healthcare v. Teva Pharmaceuticals Oral Arguments appeared first on IPWatchdog.com | Patents & Patent Law.
Industry Reaction to Helsinn Healthcare v. Teva Pharmaceuticals Oral Arguments
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- A Stylized Word Mark in One Country May Be Too Simple and Common in Another
- Other Barks & Bites for Friday, May 22: Copyright Office Issues Section 512 Safe Harbor Report, CAFC Denies Review of PTAB Institution Decision and Director Iancu on Possible Filing Deadline Extension
- CAFC Finds Claim for Delivery Notification System Abstract as Directed to a Longstanding Commercial Practice
- PTAB Institution Data Analysis Proves That Reforms Have Failed
- Non-Limiting Preamble Costs Cochlear at CAFC
Recent Posts
- A Stylized Word Mark in One Country May Be Too Simple and Common in Another
- Other Barks & Bites for Friday, May 22: Copyright Office Issues Section 512 Safe Harbor Report, CAFC Denies Review of PTAB Institution Decision and Director Iancu on Possible Filing Deadline Extension
- CAFC Finds Claim for Delivery Notification System Abstract as Directed to a Longstanding Commercial Practice
- PTAB Institution Data Analysis Proves That Reforms Have Failed
- Non-Limiting Preamble Costs Cochlear at CAFC